Journal of Clinical Oncology, Vol 25, No 20 (July 10), 2007: pp. 2873-2883
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.11.0932
Role of Surgery in Ovarian Carcinoma
Amanda Nickles Fader,
Peter G. Rose
From the Cleveland Clinic, Cleveland, OH
Address reprint requests to Peter G. Rose, MD, Cleveland Clinic Foundation, 9500 Euclid Ave, A-81, Cleveland, OH 44195; e-mail: rosep{at}ccf.org
Surgery plays a critical role in the optimal management of all stages of ovarian carcinoma. In apparent early-stage ovarian cancer, a comprehensive surgical evaluation allows stratification of patients into low- and high-risk categories. Low-risk patients may be candidates for fertility-sparing surgery and can safely avoid chemotherapy and be observed. Treatment of patients with high-risk early- or advanced-stage ovarian cancer usually requires a combined modality approach. Although it is well known that epithelial ovarian cancer is moderately chemosensitive, what distinguishes it most from other metastatic solid tumors is that surgical cytoreduction of tumor volume is highly correlated with prolongation of patient survival. Procedures such as radical pelvic surgery, bowel resection, and aggressive upper abdominal surgery are commonly required to achieve optimal cytoreduction. Women who develop recurrent disease may be eligible for a secondary cytoreductive surgery or may require a surgical intervention to palliate disease-related symptoms. For women at high risk of ovarian cancer, prophylactic bilateral salpingo-oophorectomy significantly reduces the incidence of this disease. The purpose of this article is to provide a comprehensive review of the surgical management of ovarian carcinoma. The roles of primary, interval, and secondary cytoreductive surgeries; second-look procedures; and palliative surgery are reviewed. The indications for fertility-sparing and minimally invasive surgery as well as the current guidelines for prophylactic surgery in high-risk mutation carriers are also discussed.
Authors' disclosures of potential conflicts of interest and author contributions are found at the end of this article.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
This article has been cited by other articles:

|
 |

|
 |
 
S. Aebi, M. Castiglione, and On behalf of the ESMO Guidelines Working Group
Newly and relapsed epithelial ovarian carcinoma: ESMO Clinical Recommendations for diagnosis, treatment and follow-up
Ann. Onc.,
May 1, 2009;
20(suppl_4):
iv21 - iv23.
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
D. Yamada
The Role of Surgery in Ovarian Cancer Management
ASCO Educational Book,
January 1, 2009;
2009(1):
302 - 307.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. Mabuchi, Y. Terai, K. Morishige, A. Tanabe-Kimura, H. Sasaki, M. Kanemura, S. Tsunetoh, Y. Tanaka, M. Sakata, R. A. Burger, et al.
Maintenance Treatment with Bevacizumab Prolongs Survival in an In vivo Ovarian Cancer Model
Clin. Cancer Res.,
December 1, 2008;
14(23):
7781 - 7789.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
S. A. Cannistra and W. P. McGuire
Progress in the Management of Gynecologic Cancer
J. Clin. Oncol.,
July 10, 2007;
25(20):
2865 - 2866.
[Full Text]
[PDF]
|
 |
|
|